Trial Profile
To investigate changes in antiretroviral treatment in Hepatitis-C co-infected patients during treatment with direct acting antivirals
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Jan 2017
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 04 Jan 2017 New trial record